Odimma Therapeutics Secures €2 Million to Complete the Preparation of Its First-in-Man Clinical Trial
Odimma Therapeutics, a biotechnology company specialized in personalized cancer immunotherapy announces a seed fundraising of €2 million in order to secure the preparation on its First-in-Man clinical
United Kingdom Jean Marc Limacher Patrick Squiban Europe Illkirch Pascale Balducchi Business Angels Network
Source: finanznachrichten.de